GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Royalty Corp (NAS:XOMAP.PFD) » Definitions » Capex-to-Operating-Income

XOMAP.PFD (XOMA Royalty) Capex-to-Operating-Income : 0.00 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is XOMA Royalty Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

XOMA Royalty's Capital Expenditure for the three months ended in Mar. 2025 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2025 was $5.93 Mil.

Hence, XOMA Royalty's Capex-to-Operating-Income for the three months ended in Mar. 2025 was 0.00.


XOMA Royalty Capex-to-Operating-Income Historical Data

The historical data trend for XOMA Royalty's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Royalty Capex-to-Operating-Income Chart

XOMA Royalty Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 1.51 - - -

XOMA Royalty Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of XOMA Royalty's Capex-to-Operating-Income

For the Biotechnology subindustry, XOMA Royalty's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XOMA Royalty's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XOMA Royalty's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where XOMA Royalty's Capex-to-Operating-Income falls into.


;
;

XOMA Royalty Capex-to-Operating-Income Calculation

XOMA Royalty's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.02) / -9.072
=N/A

XOMA Royalty's Capex-to-Operating-Income for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / 5.929
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XOMA Royalty  (NAS:XOMAP.PFD) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


XOMA Royalty Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of XOMA Royalty's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


XOMA Royalty Business Description

Traded in Other Exchanges
Address
2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.